Image de couverture de livre

Safety of BI 1358894 in patients with major depressive disorder: Results and learnings from a phase II randomized decentralized clinical trial

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Christopher Reist, Peide Li, Thuy Le Nguyen, Sigurd D. Süssmuth
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Clinical and Translational Science
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Safety, tolerability, and pharmacokinetics of single‐ and multiple‐ascending doses of olamkicept: Results from randomized, placebo‐controlled, first‐in‐human phase I trials
par: Frank‐Dietrich Wagner, et autres
Publié: (2024)

Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours
par: Rachel N. Grisham, et autres
Publié: (2026)

Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials
par: Matthew P. Kosloski, et autres
Publié: (2024)

Correction to Pharmacokinetics and pharmacodynamics of itepekimab in adults with moderate‐to‐severe atopic dermatitis: Results from two terminated phase II trials
Publié: (2024)

Esketamine hydrochloride in the management of moderate‐to‐severe depressive symptoms in patients undergoing multiple wound repair surgeries: A multi‐centre randomized, double‐blind, placebo‐controlled trial
par: Xiaomeng Yu, et autres
Publié: (2026)

The functional role of the pulvinar in discriminating between objective and subjective cognitive impairment in major depressive disorder
par: Burak Yulug, et autres
Publié: (2024)

Bortezomib in previously treated phosphatase and tension homology‐deficient patients with advanced intrahepatic cholangiocarcinoma: An open‐label, prospective and single‐centre phase II trial
par: Tian‐mei Zeng, et autres
Publié: (2024)

HepAssis2 ® bioartificial liver system in treating acute‐on‐chronic liver failure patients: Findings from a phase 1 randomised, open‐label clinical trial
par: Zibiao Zhong, et autres
Publié: (2026)

A phase I, randomized, placebo‐controlled trial to evaluate the pharmacokinetics, safety, and tolerability of nirsevimab in healthy Chinese adults
par: Xiaomeng Mao, et autres
Publié: (2024)

Assessing the net financial benefits of employing digital endpoints in clinical trials
par: Joseph A. DiMasi, et autres
Publié: (2024)

Proof of Pharmacology, Safety, and Pharmacokinetics of the Novel TRPA1 Antagonist BI 1839100: A Randomized, Placebo‐Controlled, Parallel Group, First‐In‐Human Study in Healthy Male Participants
par: Marella C. E. van Ruissen, et autres
Publié: (2025)

Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open‐label, multiple‐dose study
par: Andrew D. Hershey, et autres
Publié: (2024)

Safety, pharmacokinetics, and pharmacodynamics of ART‐648, a PDE4 inhibitor in healthy subjects: A randomized, placebo‐controlled phase I study
par: Akira Tanaka, et autres
Publié: (2024)

Safety, pharmacokinetics, and pharmacodynamics of anti‐IL‐4Rα antibody SHR‐1819 in healthy subjects: A randomized, controlled phase I study
par: Na Li, et autres
Publié: (2024)

Crosstalk between fibroblasts and immunocytes in fibrosis: From molecular mechanisms to clinical trials
par: Xingpeng Di, et autres
Publié: (2024)

Prednisolone versus antihistamine for allergic rhinitis: No significant difference found in randomized trial
par: Carl Skröder, et autres
Publié: (2025)

Long‐term effects of adjunctive eslicarbazepine acetate in adult Asian patients with refractory focal seizures: Post hoc analysis of a phase III trial
par: Sang Kun Lee, et autres
Publié: (2024)

Implementing a pragmatic clinical trial to tailor opioids for chronic pain on behalf of the IGNITE ADOPT PGx investigators
par: Todd C. Skaar, et autres
Publié: (2024)

Machine learning–enhanced screening funnel for clinical trials in Alzheimer's disease
par: Scott Gladstein, et autres
Publié: (2025)

What motivates people with type 2 diabetes mellitus to participate in clinical trials from home?
par: Julia Kopanz, et autres
Publié: (2024)

Efficacy and safety of pyrotinib combined with albumin‐bound paclitaxel as first‐line treatment for HER2‐positive metastatic breast cancer in patients previously treated with adjuvant and/or neoadjuvant trastuzumab therapy: The stage 1 results of a single‐arm, phase 2 prospective clinical trial
par: Xiaochu Man, et autres
Publié: (2024)

Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients
par: Eva Thijssen, et autres
Publié: (2024)

Use cases of registry‐based randomized controlled trials—A review of the registries' contributions and constraints
par: Nadine Kubesch, et autres
Publié: (2024)

Dupilumab induces a significant decrease of food specific immunoglobulin E levels in pediatric atopic dermatitis patients
par: Lisa P. van der Rijst, et autres
Publié: (2024)

Exploring the discrepancies between clinical trials and real‐world data: A small‐cell lung cancer study
par: Luca Marzano, et autres
Publié: (2024)

Safety and efficacy of isocitrate dehydrogenase‐1 inhibitor ivosidenib in patients with cholangiocarcinoma
par: Lindsay Wong, et autres
Publié: (2026)

Safety, pharmacokinetics and efficacy of selumetinib in Chinese adult and paediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas: The primary analysis of a phase 1 open‐label study
par: Zhichao Wang, et autres
Publié: (2024)

Comprehensive multi‐omics analysis of resectable locally advanced gastric cancer: Assessing response to neoadjuvant camrelizumab and chemotherapy in a single‐center, open‐label, single‐arm phase II trial
par: Yuzhou Zhao, et autres
Publié: (2024)

Programmed death‐ligand 1 expression and prognostic significance in bevacizumab treated ovarian cancer patients: Results from the phase IV MITO16A/MaNGO OV‐2 translational study
par: Francesca Basso‐Valentina, et autres
Publié: (2025)

Exploring postictal recovery with acetaminophen or nimodipine: A randomized‐controlled crossover trial
par: Julia C. M. Pottkämper, et autres
Publié: (2024)

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
par: Shang‐Gin Wu, et autres
Publié: (2024)

Distinct MAIT cell phenotypes associated with sepsis clinical outcome in emergency department patients
par: Johanna Emgård, et autres
Publié: (2025)

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1820 (Tarperprumig) in Healthy Adults: Results of a Phase I Study
par: Avner Sandhu, et autres
Publié: (2025)

Effect of long‐term treatment with memantine on mortality in patients with major cognitive disorders: A systematic review and meta‐analysis
par: Victoria Zolnowski‐Kolp, et autres
Publié: (2025)

Infantile Krabbe disease (0–12 months), progression, and recommended endpoints for clinical trials
par: Melissa R. Greco, et autres
Publié: (2024)

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study
par: Joaquina C. Baranda, et autres
Publié: (2024)

High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID ‐19 Treatment
par: Eric J. Lenze, et autres
Publié: (2025)

Proteomic profiling of the serum of patients with COVID‐19 reveals key factors in the path to clinical improvement
par: Hye Seong, et autres
Publié: (2025)

No clinically relevant electrocardiogram effects in a randomized TQT study of single therapeutic/supratherapeutic rimegepant doses in healthy adults
par: Rajinder Bhardwaj, et autres
Publié: (2024)

Pharmacokinetics and pharmacodynamics of mibavademab (a leptin receptor agonist): Results from a first‐in‐human phase I study
par: Andrew Gewitz, et autres
Publié: (2024)